Abstract: In 2014, the American Association of Oral and Maxillofacial Surgery recommended surgical treatment for medication-related osteonecrosis of the jaw (MRONJ) patients classified as stage 3 or those with mobile segments of bony sequestrum. However, there is limited information regarding the healing mechanism in MRONJ surgical treatments. This study aimed to retrospectively elucidate clinical outcomes of the surgical treatment of MRONJ patients. This study included 26 patients (7 men, 19 women; age: 42-92 years; mean ± standard deviation, 75.3 ± 11.7 years) who were classified as stage 3 or had mobile segments of bony sequestrum, and intake of the offending drug was ceased. The sequestrum was removed with surrounding vital bone, and segmental resection was performed in one patient with a pathological mandibular fracture. The outcome was classified into one of the following three categories: "Healing," "Improvement," "Unchanged." and "Exacerbation." The mean postoperative follow-up period was 16.6 months (3.0 -57.9 months), and complete healing was observed in 21 patients (80.8%), improvement of the lesion was observed in four patients (15.4%), and the outcome of one patient was unchanged (3.8%). The procedure described here may be recommended with relatively high clinical success rate for the patients with MRONJ requiring surgical treatment.
Introduction
Bisphosphonates (BPs) inhibit bone resorption and are commonly used for treating bone-resorbing diseases such as osteoporosis, malignancy-related hypercalcemia, multiple myeloma, and bone metastasis from solid cancers 1) . BPs are unstable equivalents of pyrophosphates that selectively bind to bone and selectively act on osteoclasts during high bone turnover, resulting in an antiresorptive effect 2) . Despite the advantageous clinical effects of BP for treating several diseases, some adverse reactions have been reported including bisphosphonate-related osteonecrosis of the jaws (BRONJ) [3] [4] [5] . Similarly, denosumab, an antihuman RANK ligand (RANKL) monoclonal antibody that was developed to inhibit osteoclasts during the treatment of boneresorbing diseases, is reported to cause osteonecrosis of the jaw (ONJ) 6, 7) ; this has been recently termed medication-related ONJ (MRONJ) 8) .
In 2014, the American Association of Oral and Maxillofacial Surgery (AAOMS) published recommendations for stage-specific treatment of MRONJ 8) . These recommendations reflected those stated in 2007 and 2009 for BRONJ, namely, supportive conservative therapy and surgical treatment for patients classified as stage 3 or those with mobile segments of bony sequestrum.
However, clear evidence regarding the mechanism of the healing process in MRONJ treatment has not been previously reported. In this study, we retrospectively evaluated the histopathological and radiological aspects of postoperative outcomes of surgical treatment in MRONJ patients. update defines MRONJ stage 3 as "exposed and necrotic bone, or fistulae that probe to bone, with evidence of infection" and at least one of the following: "exposed necrotic bone extending beyond the region of the alveolar bone, i.e., inferior border and ramus of the mandible, maxillary sinus, and zygoma in the maxilla," "pathologic fracture," "extra-oral fistula," "oral antral/ oral nasal communication," and "osteolysis extending to the inferior border of the mandible or sinus floor" 8) .
Materials and Methods Patients
Conservative treatment with oral antibiotics and oral rinsing was performed before surgery, but this did not lead to healing of the defect. The extent of necrosis was evaluated using computed tomography (CT) and panoramic image.
The aim of the surgery was to remove the sequestrum as well as the surrounding vital bone. Thereafter, the affected bone was resected until healthy, perfused (bleeding) bone was observed (Fig.  1) . In case of sequestration formation with a pathological fracture, segmental resection of the extensive necrotic bone and pathological fracture in the mandible was performed with safety margins extending to the living bone. Furthermore, the BP or denosumab treatment was interrupted 3 months before the operation, and a different treatment regime was chosen in consultation with the physician in charge of treatment of MRONJ. This study was approved by the Ethics Committee of Kagawa Prefectural Central Hospital (Approval No.492). Written informed consent was obtained from the patient for publication of this study and any accompanying images.
Outcomes
The postoperative clinical and functional statuses of patients were assessed for 3 months or longer using clinical and radiographical examinations. Histopathological analysis of the bone specimens demonstrated no metastatic disease, and confirmed a diagnosis of MRONJ in all cases.
Patients with follow-up periods >3 months were evaluated 6 months after surgery, and the presence or absence of changes in disease state was assessed.
The evaluation method proposed by Reich et al. 9) was used and includes the following: Primary cause of the disease The treatment of osteoporosis was the most common indication for BP and/or denosumab, and this was observed in 20 patients (76.9%). The indications for treatment in the remaining patients included multiple myeloma (n = 3, 11.5%), breast carcinoma (n = 2, 7.7%), and prostate carcinoma (n = 1, 3.8%).
Location
The lesion was located in the maxilla in eight (30.8%) patients and mandible in 18 (69.2%) patients.
Stage classification
With regard to the AAOMS stage classification, 21 patients 
Triggering factor
The following triggering factors of MRONJ were identified: tooth extraction (n = 14, 53.8%), periodontal disease (n = 3, 11.5%), natural occurrence (n = 2, 7.7%), denture incompatibility (n = 2, 7.7%), pericoronitis of the wisdom tooth (n = 1, 3.8%), dental implant infection (n = 1, 3.8%), and unknown cause (n = 3, 11.5%).
Results
Surgical outcome (Table 1) The mean follow-up period was 16.6 months (3.0-57.9 months), twenty-five patients underwent sequestrum removal surgery, while one patient with a mandibular pathological fracture underwent segmental resection. With regard to the outcome of the surgery, complete healing was observed in 21 patients (80.8%), improvement of the lesion was observed in four patients (15.4%), and the condition remained unchanged in one patient (3.8%).
Representative case reports After removal of the sequestrum and surrounding vital bone, a panoramic X-ray image showed a large radiolucent area extending from the second premolar to the wisdom tooth in the right mandible. Gradual bone regeneration in the left lower molar region was observed, and a radiographic image taken 1 year after surgery showed complete filling of the mandibular cavity by newly generated bone. The patient was well at the 2-year follow-up. Case 2 (Fig. 4) A 92-year-old woman was referred to the Division of Oral and with an osteosynthesis locking plate at the time of resection, and was well at the 2-year follow-up.
Histological evaluation
Loupe image showed a mixture of sequestration and viable bone (Fig.5A) . Microscopic examination showed necrotic bony trabeculae with empty osteocyte lacunae. The necrotic bone was surrounded by bacterial colonies and exhibited irregular peripheral resorption and prominent reversal lines (Fig. 5D) . Empty Howship's lacunae were frequently observed at the periphery of the bone, suggesting that the osteoclasts had undergone apoptosis after internalizing bisphosphonates. These findings confirmed a diagnosis of BRONJ. Viable bone areas and numerous multinucleated osteoclasts were observed at the periphery of the bony trabeculae and in the intertrabecular spaces (Fig.5B) . Active osteocytes and osteoblasts were observed on the periphery of the bone surface, suggesting the occurrence of proper bone remodeling (Fig.5C ). The intertrabecular spaces were infiltrated by inflammatory cells including neutrophils, lymphocytes, and plasma cells.
Discussion MRONJ can be caused by various agents, and the risk depends on the type, dosage, and duration of the medication. The risk of ONJ in cancer patients in clinical trials was 0-0.019% (0-1.9 cases per 10,000 cancer patients) [10] [11] [12] , while the risk of ONJ in cancer patients on denosumab treatment was comparable to that of patients receiving zolendronate [13] [14] [15] . The risk of ONJ among osteoporosis patients treated with zolendronate or denosumab (0.017-0.04%) was similar to that of patients enrolled (0-0.02%) 8) . The duration of BP or antiresorptive therapy remains a risk factor for ONJ. Among patients receiving zolendronate or denosumab treatment, the risk of ONJ incidence increased two to three times when these agents were used for more than 3 years 13) . A further increase in the number of MRONJ patients is expected in the future, although its treatment is still under discussion.
The international consensus for MRONJ treatment includes conservative measures initially 8) , followed by surgical therapy if no effect is observed. The reported success rates vary considerably, including approximately 12-100% 16) , 54% of 33 patients 17) , and 23% of 29 patients 18) . However, comparisons of different studies are limited by the fact that different criteria may be used to define the success of treatment outcomes. Some studies define success as the absence of infection and cessation of disease progression, while others define a successful treatment outcome as normal oral mucosa without any sign of exposed bone. Hoff et al. 18) and Lazarovici et al. 19) in their retrospective analyses of patients treated conservatively or with superficial debridement reported complete healing in only 23% and 18% of patients, respectively. The low rates of complete healing following conservative or minimal surgical treatment (only sequestrectomy) of established MRONJ have resulted in an increased interest in the performance of more extensive surgery for this disease. In our study, removal of sequestrum as well as the surrounding vital bone was performed after cessation of the medication. In case of sequestration formation, oral soft tissues can be used to easily close the socket of the removed sequestrum and bony edge completely. After the affected bone is removed and the bony edges are rounded off, a mucoperiosteal flap is elevated and moved for closure. The use of good surgical technique with adequate removal of sequestrum and soft tissue closure results in a predictable treatment outcome, with some authors reporting a success rate of 85-100% with uncompli cated int rao ral wo und healing after surgical treatment 16, 20, 21) . Although closure using the local skin flap has exhibited high success rates 22, 23) , our treatment method benefits from being minimally invasive and having the same effect without requiring a local flap.
Osteoclasts, a specific target cell of BP, play a central role in physiological and pathological bone resorption. However, this medication inhibits their differentiation and function and increases their apoptosis, leading to decreased bone resorption and remodeling [24] [25] [26] . Weinstein et al. reported greater presence of osteoclasts in biopsy specimens collected from the iliac bone of healthy postmenopausal women receiving oral BP therapy than in those from patients who were receiving placebo 27) . A number of giant and hypernucleated osteoclasts with 20-40 nuclei, of which approximately 30% were apoptotic, were observed to detach from the bone surface, suggesting that BPs prolonged the apoptosis of osteoclasts while cell fusion continued to generate distinctive morphology such as giantism and hypernucleation. In patients undergoing BP treatment, the drug is believed to inactivate and induce apoptosis of osteoclasts, instead of reducing their numbers. In case 2 of our study, giant and hypernucleated osteoclasts were not observed, suggesting that the effect of the BP had been lost during long-term withdrawal.
Moreover, osteoclasts have been known to indirectly assist bone formation, wherein osteoclastic bone resorption results in the release of some growth factors in the bone which stimulate osteoblasts to produce bones 27) . The interaction of osteoclasts with osteoblasts is thought to be essential for bone turnover. Thus, the loss of osteoclasts is likely to impair the activity of osteoblasts, resulting in bone turnover arrest and osteonecrosis. On the other hand, the direct effects of BP on osteoblasts have also been investigated. Zoledronate inhibited the growth and viability of osteoblasts 28, 29) , which in turn inhibits bone healing. In a representative case1 included in the present study, bone healing of the mandible after cessation of medication and sequestrum removal was apparent radiologically. Additionally, strong osteoblast activity was also observed histologically, suggesting that a "drug holiday" or discontinuation of drugs may be effective in the treatment of MRONJ. The treatment of MRONJ may be associated with damage to osteoblasts, and this hypothesis is supported by a study that reported that the parathyroid hormone may improve MRONJ by stimulating osteoblasts 30) . However, in patients treated with BP therapy, a drug holiday seems to be maximally effective for restoring bone turnover of the jaw and supporting the treatment of MRONJ. Although sequestrum removal surgery with a drug holiday is a useful method for MRONJ treatment, these measures should only be selected based on the general condition of the patient and the local state.
The treatment measures used in this study showed a good healing rate of 96.2% (complete healing: 80.8%; improvement:
15.4%) and should be, therefore, considered a more effective treatment in the requiring surgery patients with free sequestration in our surgical strategy.
In conclusion, this clinical retrospective study of treatment of MRONJ showed that sequestrum may be formed despite a drug holiday, and the use of a surgical technique to adequately remove it, accompanied by soft tissue closure, results in predictable treatment outcomes.
